KR20160008523A - 종양 독성과 mri를 위한 표적화 콜롤 - Google Patents

종양 독성과 mri를 위한 표적화 콜롤 Download PDF

Info

Publication number
KR20160008523A
KR20160008523A KR1020157030349A KR20157030349A KR20160008523A KR 20160008523 A KR20160008523 A KR 20160008523A KR 1020157030349 A KR1020157030349 A KR 1020157030349A KR 20157030349 A KR20157030349 A KR 20157030349A KR 20160008523 A KR20160008523 A KR 20160008523A
Authority
KR
South Korea
Prior art keywords
targeted
nanoparticles
colol
hermn
cholol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157030349A
Other languages
English (en)
Korean (ko)
Inventor
라일 케이. 메디나-카우웨
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Publication of KR20160008523A publication Critical patent/KR20160008523A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157030349A 2013-05-08 2014-05-08 종양 독성과 mri를 위한 표적화 콜롤 Ceased KR20160008523A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
US61/821,106 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Publications (1)

Publication Number Publication Date
KR20160008523A true KR20160008523A (ko) 2016-01-22

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157030349A Ceased KR20160008523A (ko) 2013-05-08 2014-05-08 종양 독성과 mri를 위한 표적화 콜롤

Country Status (16)

Country Link
US (2) US9757386B2 (https=)
EP (2) EP3730155A1 (https=)
JP (1) JP6640715B2 (https=)
KR (1) KR20160008523A (https=)
CN (2) CN108451930A (https=)
AU (2) AU2014262653B2 (https=)
CA (1) CA2910030A1 (https=)
DK (1) DK2993983T3 (https=)
ES (1) ES2791043T3 (https=)
IL (1) IL265935B (https=)
MX (1) MX2015015434A (https=)
PL (1) PL2993983T3 (https=)
PT (1) PT2993983T (https=)
RU (1) RU2674146C2 (https=)
WO (1) WO2014182868A1 (https=)
ZA (1) ZA201508092B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
US9850293B2 (en) 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
EP3687998A4 (en) * 2017-08-31 2021-05-19 Technion Research & Development Foundation Limited CORROL COMPOSITIONS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6939963B2 (en) * 2001-07-02 2005-09-06 Technion Research And Development Foundation Ltd. Method for the preparation of selectively-substituted corroles and new substituted corroles
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US8791099B2 (en) * 2007-08-28 2014-07-29 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
ATE556708T1 (de) * 2008-01-31 2012-05-15 Technion Res & Dev Foundation Corrole für neuroprotektion und neuro-rescue
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
US20130065778A1 (en) 2010-01-26 2013-03-14 Yale University MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
US9850293B2 (en) 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
BR112018074304A2 (pt) 2016-05-27 2019-10-01 Cedars Sinai Medical Center composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos

Also Published As

Publication number Publication date
EP2993983B1 (en) 2020-03-25
CN105307499A (zh) 2016-02-03
JP2016526021A (ja) 2016-09-01
DK2993983T3 (da) 2020-05-18
CN108451930A (zh) 2018-08-28
US20140335025A1 (en) 2014-11-13
ES2791043T3 (es) 2020-10-30
PL2993983T3 (pl) 2020-09-07
US20170281802A1 (en) 2017-10-05
RU2674146C2 (ru) 2018-12-07
RU2015152033A (ru) 2017-06-16
PT2993983T (pt) 2020-05-22
AU2018250401B2 (en) 2020-06-11
AU2014262653B2 (en) 2018-07-26
RU2015152033A3 (https=) 2018-04-25
ZA201508092B (en) 2017-02-22
HK1221870A1 (en) 2017-06-16
EP2993983A4 (en) 2017-01-11
IL265935B (en) 2020-06-30
AU2018250401A1 (en) 2018-11-08
JP6640715B2 (ja) 2020-02-05
EP3730155A1 (en) 2020-10-28
IL265935A (en) 2019-05-30
WO2014182868A1 (en) 2014-11-13
US10709801B2 (en) 2020-07-14
US9757386B2 (en) 2017-09-12
EP2993983A1 (en) 2016-03-16
AU2014262653A1 (en) 2015-11-12
MX2015015434A (es) 2016-03-15
CA2910030A1 (en) 2014-11-13
CN105307499B (zh) 2018-04-27

Similar Documents

Publication Publication Date Title
AU2018250401B2 (en) Targeting corroles for tumor toxicity and mri
US20210085789A1 (en) Pharmaceutical composition for cancer treatment
US12569560B2 (en) Bismuth-gadolinium nanoparticles
Hou et al. A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery
Peng et al. Covalent organic framework based cytoprotective therapy after ischemic stroke
CN113993554A (zh) 选自食道、咽喉、肺、脑和肠的癌症的靶向化合物
US20170333366A1 (en) Casein Coated Drug-Loaded Iron Oxide Nanoparticles
Nasr Azadani et al. Nanoparticles in cancer theranostics: Focus on gliomas
US20240074974A1 (en) Methods and related compositions for the treatment of cancer
Liu et al. Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma
HK1221870B (en) Targeting corroles for tumor toxicity and mri
HK1260403A1 (en) Targeting corroles for tumor toxicity and mri
CN120267849B (zh) 一种靶向双硫死亡的载6-氨基烟酰胺纳米材料及其制备方法和在卵巢癌中的应用
KR102671325B1 (ko) 허혈/재관류 손상의 예방 및 치료를 위한 raba 및 이를 포함하는 약리학적 조성물
Zhang et al. Black Phosphorus Quantum Dots Effectively and Safely Treat Glaucoma as a Promising Anti-Ferroptosis Nano-drug
CN118021840A (zh) 治疗神经退行性疾病的纳米酶及用途
Libby et al. DDIS-01. INHIBITION OF BRAIN TUMOR INITIATING CELL GROWTH VIA NOVEL GLUCOSE TRANSPORTER ANTAGONISTS
TW201223539A (en) Chemo-preventive and chemo-therapeutic effects of polypeptide on cellular proliferative disorder

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151021

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200615

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201013

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200615

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I